 Effect gliclazide treatment insulin release sensitivity endogenous insulin NIDDM role initial continuous subcutaneous insulin infusion-induced normoglycemia obese new-onset non-insulin-dependent diabetes NIDDM patients group continuous subcutaneous insulin infusion CSII normoglycemia days blood glucose mmol/L mean daily blood glucose mmol/L end CSII period excellent glycemic control insulin day hours Endogenous insulin production urinary C-peptide hours Gliclazide group CSII obese NIDDM patients group habitual hyperglycemic state Gliclazide group group excellent metabolic control appearance small first-phase insulin response intravenous glucose significant increases mean-daily-insulin mean-daily-blood-glucose ratio urinary C-peptide-to-glucose ratio gliclazide effects pronounced group No significant effect efficacy endogenous insulin slope disappearance blood glucose insulin levels months gliclazide treatment excellent glycemic control patients unchanged stimulation gliclazide first-phase insulin response mean insulin-to-glucose urinary C-peptide-to-glucose ratios change ratio glucose disposal endogenous insulin physiologic insulin replacement normoglycemia NIDDM insulin resistance clinical significance gliclazide beta-cell-stimulating action unchanged months therapeutic effect gliclazide NIDDM result beta-cytotrophic action Initial normoglycemia CSII lasting effect gliclazide action